Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer
Dato-DXd plus durvalumab achieved a 50% overall pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, according to the I-SPY 2.2 trial. The study highlights the utility of evaluating treatment response by response predictive subtype (RPS), with further investigation needed in immune-positive and hormone receptor–negative/DNA damage repair deficiency–negative subtypes. The combination showed promising results in the immune-positive and triple-negative subtypes, with over 50% of pCRs achieved by the end of block A, avoiding standard chemotherapy.
Related Clinical Trials
Reference News
Dato-DXd plus durvalumab achieved a 50% pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, according to the I-SPY 2.2 trial. The study emphasizes evaluating treatment response per response predictive subtype (RPS) and suggests further investigation in immune-positive and hormone receptor (HR)-negative/DNA damage repair deficiency (DRD)-negative subtypes. The combination's efficacy was supported by the BEGONIA trial, showing a 79% objective response rate in metastatic triple-negative breast cancer. The I-SPY 2.2 trial design uses RPS to optimize drug assignment, aiming to improve efficacy and minimize toxicity.
Dato-DXd plus durvalumab achieved a 50% overall pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, according to the I-SPY 2.2 trial. The study highlights the utility of evaluating treatment response by response predictive subtype (RPS), with further investigation needed in immune-positive and hormone receptor–negative/DNA damage repair deficiency–negative subtypes. The combination showed promising results in the immune-positive and triple-negative subtypes, with over 50% of pCRs achieved by the end of block A, avoiding standard chemotherapy.
Dato-DXd plus durvalumab achieved a 50% overall pathologic complete response (pCR) rate in stage II/III high-risk HER2-negative breast cancer patients, highlighting the utility of response predictive subtype (RPS) evaluation. The I-SPY 2.2 trial's findings suggest further investigation in immune-positive and hormone receptor (HR)-negative/DNA damage repair deficiency (DRD)-negative subtypes is warranted.